Acadia Tries To Nix Investor Suit Over Drug Deaths
Acadia Pharmaceuticals on Friday sought to dismiss a proposed class action accusing it of inflating its stock price by hiding safety risks connected to its medication for hallucinations and delusions, telling...To view the full article, register now.
Already a subscriber? Click here to view full article